A phase 3 trial of upadacitinib for giant-cell arteritis
https://www.coltonconsortium.org/publications/a-phase-3-trial-of-upadacitinib-for-giant-cell-arteritis/
Archives: “Archives”
Showing 121 - 128 of 128 posts
A randomized, double-blind, placebo-controlled trial of abatacept for the treatment of relapsing, non-severe granulomatosis with polyangiitis
https://www.coltonconsortium.org/publications/a-randomized-double-blind-placebo-controlled-trial-of-abatacept-for-the-treatment-of-relapsing-non-severe-granulomatosis-with-polyangiitis/
A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients
https://www.coltonconsortium.org/publications/a-retrospective-evaluation-of-glucagon-like-peptide-1-receptor-agonists-in-systemic-lupus-erythematosus-patients/
A single-cell atlas of circulating immune cells over the first 2 months of age in extremely premature infants
https://www.coltonconsortium.org/publications/a-single-cell-atlas-of-circulating-immune-cells-over-the-first-2-months-of-age-in-extremely-premature-infants/
An autoimmune transcriptional circuit drives FOXP3+ regulatory T cell dysfunction
https://www.coltonconsortium.org/publications/an-autoimmune-transcriptional-circuit-drives-foxp3-regulatory-t-cell-dysfunction/
Lupus Flare-Ups Strongly Linked to Specific Bacterial Growth in Gut
https://www.coltonconsortium.org/news/lupus-flare-ups-strongly-linked-to-specific-bacterial-growth-in-gut/NYU Langone researchers have linked lupus flare-ups to blooms of a specific gut bacterium, opening a potential path to probiotic and dietary treatments less toxic than current immunosuppressive therapies.
NYU Langone Joins $58M NIH Partnership to Accelerate Autoimmune Disease Research
https://www.coltonconsortium.org/news/nyu-langone-joins-58m-nih-partnership-to-accelerate-autoimmune-disease-research/NYU Langone's Colton-backed Division of Rheumatology is taking a leading role in the NIH's $58 million AMP AIM program, driving research into lupus, psoriatic disease, Sjögren's disease, and the microbiome.
How Lupus Antibodies Sabotage a Key Enzyme — and What It Means for Treating Kidney Disease
https://www.coltonconsortium.org/news/how-lupus-antibodies-sabotage-a-key-enzyme-and-what-it-means-for-treating-kidney-disease/Colton-supported NYU researchers have found that autoantibodies can physically inactivate a key enzyme in over half of lupus nephritis patients — a non-genetic mechanism that could serve as a future biomarker and therapeutic target.